Eli Lilly and Company is now a new Platinum Sponsor of the 2023 Activator program, according to Nucleate. Eli Lilly and Company (NYSE: LLY), a nonprofit organization devoted to empowering future biotech leaders, has announced that it will launch the $300K Genetic Medicine Grand Challenge and serve as a Platinum Sponsor of the 2023 Activator Program.
Eli Lilly and Company (NYSE: LLY), a nonprofit devoted to empowering future biotech leaders, has joined Nucleate as a Platinum Level Sponsor of the 2023 Activator Program. Nucleate is an organization run by academic trainees.
More than 100 venture teams in the early stages of development have received support from Nucleate's equity-free Activator program, including Glyphic, NextRNA, and Manifold Bio. As part of the first Eli Lilly and Company Genetic Medicine Grand Challenge, Lilly will award grants totaling $300,000 to innovative technologies.
The Eli Lilly and Company Genetic Medicine Grand Challenge will award three (3) grants totaling $100,000 to support novel genetic medicine technologies developed by Nucleate's community of early-career scientists.
The grants' scope will cover a range of genetic medicine subspecialties, such as genome engineering, regenerative medicine, delivery/manufacturing, and an open umbrella category. Additionally, winning proposals will have access to Lilly's extensive network of business and scientific expertise.
Researchers can submit their proposals for consideration for any of The Eli Lilly and Company Genetic Medicine Grand Challenge grants at this link. The deadline for proposals submission is March 1, 2023. Applying does not require membership in Nucleate.
Oliver Dodd, Co-President, Co-Founder, and Treasurer of Nucleate, said, "Nucleate is honored to partner with Lilly and support the next generation of biotech leaders and transformative technologies for genetic medicine. In addition to thousands of industry mentors, experts, and advisors, we have developed a global community of more than 600 scientist-innovators affiliated with 120 academic institutions.
We will be able to demonstrate what this community can accomplish when working together to address common unmet needs for patients suffering from crippling disease thanks to the Eli Lilly and Company Genetic Medicine Grand Challenge Grants.
According to Geraldine Ezeka, EVP of Culture at Nucleate, "having the support of a pioneering and fundamental pharmaceutical company like Lilly is a transformative moment for our organization." "We are excited to take advantage of Lilly's skilled and knowledgeable network of scientists, businesspeople, and investors.
We will create a lasting link between academia and industry with the help of our community of enthusiastic and diverse early-career scientists. This will lead to increased innovation, lifelong friendships, and mentor-mentee relationships.
Regarding Nucleate:
A nonprofit organization called Nucleate is committed to developing the next generation of biotech leaders. Nucleate ignites new intellectual communities and integrates emerging talent within a global biotech community with chapters spanning 18 geographical regions and participation from over 120 academic institutions.
Nucleate supports democratizing biotech innovation by removing barriers and assisting founders in focusing on developing game-changing technologies through open-access educational programming. For more information, go to http://www.nucleate.xyz, and if you want to participate in our programming, send an email to contact@nucleate.xyz.